Ocugen, Inc. (OCGN) stock
OCGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.83−0.05 (-5.24%)
Close on Nov 13, 2026Market cap $280.72MP/E –Yield –
Ocugen r&d expenses
Research and development expenses are spending on new products and technology.
Ocugen's R&D Expenses for the twelve months ending Sep 30, 2026 was $45.11M, up 20.7% year over year. For fiscal 2025 it was $39.75M, up 23.7% from the year before. Over ten years it grew 5.5% a year on average. The highest annual figure on record is $56.16M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.75M | +23.7% |
| FY2024 | Dec 31, 2024 | $32.13M | -18.8% |
| FY2023 | Dec 31, 2023 | $39.57M | -29.5% |
| FY2022 | Dec 31, 2022 | $56.16M | +60.0% |
| FY2021 | Dec 31, 2021 | $35.11M | +452.5% |
| FY2020 | Dec 31, 2020 | $6.35M | -21.4% |
| FY2019 | Dec 31, 2019 | $8.09M | -21.7% |
| FY2018 | Dec 31, 2018 | $10.32M | -33.7% |
| FY2017 | Dec 31, 2017 | $15.57M | -27.9% |
| FY2016 | Dec 31, 2016 | $21.58M | -7.2% |
| FY2015 | Dec 31, 2015 | $23.24M | -10.7% |
| FY2014 | Dec 31, 2014 | $26.04M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $12.50M | +12.1% |
| Q2 FY2026 | Jun 30, 2026 | $10.69M | +27.2% |
| Q1 FY2026 | Mar 31, 2026 | $11.26M | +18.1% |
| Q4 FY2025 | Dec 31, 2025 | $10.67M | +28.7% |
| Q3 FY2025 | Sep 30, 2025 | $11.15M | +37.5% |
| Q2 FY2025 | Jun 30, 2025 | $8.40M | -5.6% |
| Q1 FY2025 | Mar 31, 2025 | $9.53M | +39.6% |
| Q4 FY2024 | Dec 31, 2024 | $8.29M | +6.6% |
| Q3 FY2024 | Sep 30, 2024 | $8.11M | +15.0% |
| Q2 FY2024 | Jun 30, 2024 | $8.90M | -38.9% |
| Q1 FY2024 | Mar 31, 2024 | $6.83M | -32.9% |
| Q4 FY2023 | Dec 31, 2023 | $7.78M | -54.8% |
| Q3 FY2023 | Sep 30, 2023 | $7.05M | -60.7% |
| Q2 FY2023 | Jun 30, 2023 | $14.57M | +25.6% |
| Q1 FY2023 | Mar 31, 2023 | $10.17M | +8.3% |
| Q4 FY2022 | Dec 31, 2022 | $17.23M | +142.6% |
| Q3 FY2022 | Sep 30, 2022 | $17.94M | +185.6% |
| Q2 FY2022 | Jun 30, 2022 | $11.60M | -38.5% |
| Q1 FY2022 | Mar 31, 2022 | $9.39M | +227.1% |
| Q4 FY2021 | Dec 31, 2021 | $7.10M | +345.5% |
| Q3 FY2021 | Sep 30, 2021 | $6.28M | +325.0% |
| Q2 FY2021 | Jun 30, 2021 | $18.85M | +1056.6% |
| Q1 FY2021 | Mar 31, 2021 | $2.87M | +73.8% |
| Q4 FY2020 | Dec 31, 2020 | $1.59M | -8.8% |
| Q3 FY2020 | Sep 30, 2020 | $1.48M | +13.2% |
| Q2 FY2020 | Jun 30, 2020 | $1.63M | +31.4% |
| Q1 FY2020 | Mar 31, 2020 | $1.65M | -56.4% |
| Q4 FY2019 | Dec 31, 2019 | $1.75M | -40.1% |
| Q3 FY2019 | Sep 30, 2019 | $1.31M | -16.4% |
| Q2 FY2019 | Jun 30, 2019 | $1.24M | -72.2% |
| Q1 FY2019 | Mar 31, 2019 | $3.79M | +15.4% |
| Q4 FY2018 | Dec 31, 2018 | $2.92M | -13.4% |
| Q3 FY2018 | Sep 30, 2018 | $1.56M | -55.2% |
| Q2 FY2018 | Jun 30, 2018 | $4.46M | +5.9% |
| Q1 FY2018 | Mar 31, 2018 | $3.29M | -27.0% |
| Q4 FY2017 | Dec 31, 2017 | $3.37M | -36.7% |
| Q3 FY2017 | Sep 30, 2017 | $3.49M | – |
| Q2 FY2017 | Jun 30, 2017 | $4.21M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.50M | – |
| Q4 FY2016 | Dec 31, 2016 | $5.32M | – |
See a number that looks wrong?